Insulin Aspart Sanofi (Insulin Aspart)

Insulin Aspart mimics natural insulin by binding to insulin receptors on muscle, fat, and liver cells. This activates signaling pathways that increase glucose uptake, inhibit hepatic glucose production, and promote glycogen storage, leading to a rapid decline in circulating blood glucose after injection.

The dose of Insulin Aspart Sanofi is individualized. A qualified prescriber determines the amount based on the patient’s weight, carbohydrate intake, current blood glucose levels, and overall treatment goals. Patients should follow the dosing instructions provided by their healthcare professional.

Data on the use of Insulin Aspart during pregnancy and lactation are limited. Healthcare providers may consider it when the benefits outweigh potential risks, but the decision should be made on a case‑by‑case basis in consultation with a obstetrician or maternal‑fetal medicine specialist.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics if needed), and necessary import documentation.

Insulin Aspart has a similar onset of action (approximately 10‑20 minutes) and duration (3‑5 hours) to other rapid‑acting analogues such as insulin lispro and insulin glulisine. Clinical studies show comparable efficacy in post‑prandial glucose control, while individual patient response and tolerability may guide the choice of product.

Insulin Aspart should be stored in a refrigerator at 2‑8 °C (36‑46 °F). Keep the vial or pen in its original packaging, protect it from light, and avoid freezing. Once in use, the product may be kept at controlled room temperature (up to 30 °C) for a limited period, typically 28 days, as indicated on the label.

Insulin Aspart is administered by subcutaneous injection, usually into the abdomen, thigh, or upper arm. It can be delivered using a pre‑filled pen, vial with syringe, or an insulin pump, depending on the prescribed delivery system. Injections are typically given 5‑10 minutes before meals.

The most serious risks include severe hypoglycaemia, which can cause loss of consciousness or seizures, and allergic reactions ranging from local skin reactions to anaphylaxis. Patients should be educated on recognising early signs of low blood glucose and instructed to seek immediate medical attention for any signs of a severe allergic response.

Insulin Aspart is contraindicated in individuals with a known hypersensitivity to insulin Aspart or any of its excipients. It should also be avoided in patients with severe hypoglycaemia unresponsive to treatment, and in those for whom rapid‑acting insulin is not appropriate based on clinical judgement.